It's been a difficult road for Aastrom Biosciences (ASTM) over the past two years, but management remains committed to its platform and sees potential with ixmyelocel-T in dialated cardiomyopathy (NYSE:DCM). We will find out if the strategy pays off in 2015.
Enrollment in the Phase 2 ixCELL-DCM study, initiated in April 2013, continues on plan. The company had previously generated strong proof-of-concept in DCM. A twelve month follow-up analysis from the company's phase 2a Catheter-DCM study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) in May 2012. Slides from this presentation can be found via this link. This was a 22 patient study designed to evaluate the safety and efficacy of intra-myocardial delivery of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|